Argenx downgraded at Baird after Vyvgart trial setback (ARGX)

Core Viewpoint - Argenx SE (ARGX) shares declined following a downgrade by Baird due to valuation concerns after a setback in a late-stage trial for its leading therapy, Vyvgart [2] Company Summary - Argenx SE experienced a drop in stock price after announcing issues with its best-selling therapy, Vyvgart, which has raised concerns among analysts regarding the company's valuation [2]